[Drug-resistant B cell XXXX safely treated with rituximab to control leukemic cell increment and platelet transfusion dependence].

@entity1 @entity6113 @entity137 @entity1072 @entity3118 @entity382
A 61-year-old @entity1 was found to have mild @entity6113 during a medical checkup and was referred to our hospital in 1993. Physical examination showed a mild @entity382 , and bone marrow examination revealed the proliferation of monoclonal mature B cells. He was diagnosed with @entity1072 . Chlorambucil and then @entity3118 were effective initially. However, large transformed cells started to increase in 2000, and the increment became uncontrollable and platelet transfusion dependence developed. He was admitted to our hospital in October 2001. He intermittently received a total of 32 administrations of rituximab. The total dose was 15, 500 mg. The @entity137 was tolerable and he became transfusion independent for 6 months. However, systemic lymphoadenopathy and @entity382 did not respond to the drug. We conclude that rituximab treatment is useful for refractory @entity1072 because of its excellent safety.
